• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senators urge HHS to seek lower price for naloxone

April 19, 2018 By Sarah Faulkner

Narcan nasal sprayU.S. Sens. Debbie Stabenow (D-MI) and Gary Peters (D-MI) penned a letter to the Dept. of Health and Human Services, urging the agency to demand that manufacturers lower the price of the opioid overdose reversal drug, naloxone.

The lawmakers wrote that the price of naloxone has climbed dramatically since it was first approved by the FDA decades ago – a two-pack of the drug’s nasal spray formulation, Narcan, costs $150, according to the senators.

When the White House’s opioid commission recommended that the president declare a national emergency over the country’s opioid epidemic, they added that the president should give HHS secretary Alex Azar the power to negotiate lower pricing of naloxone for government groups.

Just this month, U.S. surgeon general Jerome Adams issued a rare public advisory calling on the public to carry naloxone.

“No police officer, no firefighter, no public health provider, and no person should be unable to save a life because of the high price,” the lawmakers wrote. “By bringing down the cost, we can get this life-saving drug in the hands of more people as called for by the Surgeon General. Doing so will save countless lives.”

Stabenow and Peters were joined by Sens. Bernie Sanders (I-VT), Angus King (I-ME) and 12 Democrats, who signed onto the letter.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat

IN CASE YOU MISSED IT

  • Medtrum introduces 300-unit tubeless insulin pump
  • Baxter reports positive smart infusion pump, EMR integration data
  • Dexcom to cease G6 CGM production next year, transition fully to G7
  • Modular Medical prices $4.7M public offering
  • Medtronic studies highlight MiniMed 780G’s cost-effectiveness

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS